Company news

Rigel Pharmaceuticals, Inc. news in 2026

Rigel Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rigel Reports Third Quarter 2026 Financial Results

November 5, 2026

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

November 4, 2026

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

October 29, 2026

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

October 19, 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 10, 2026

Rigel Reports Second Quarter 2026 Financial Results

August 4, 2026

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

July 28, 2026

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

July 1, 2026

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

June 16, 2026

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

May 21, 2026

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

May 12, 2026

Rigel Reports First Quarter 2026 Financial Results

May 5, 2026

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

April 28, 2026

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

March 30, 2026

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

February 24, 2026

Rigel Appoints Michael P. Miller to the Board of Directors

February 3, 2026

Rigel Provides Business Update and 2026 Outlook

January 12, 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

January 9, 2026

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Calls in 2026

Decks in 2026